Early Clinical Development of ARQ 197, a Selective, Non–ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced CancersAlex A. Adjei, Edward G. Garmey|The Oncologist|2011Cited by 72